Meijer Piet, Hanss Michel, Christensen Ulla, Wiman Bjorn, Kluft Kees
Gaubius Laboratory, TNO-PG, Zernikedreef 9, 2333CK Leiden, The Netherlands. Fax. ++31-71-5181496, E-mail:
Laboratoire d' Hematologie, Hopital Cardiologique, Lyon Cedex, France.
EJIFCC. 2001 Jul 22;13(2):61-66. eCollection 2001 Jul.
There is a lack of well-established criteria for the specific measurement of fibrinolytic parameters. On behalf of the SSC, the subcommittee on Fibrinolysis started a process to develop criteria for the specific measurement of fibrinolytic variables. This report describes the criteria for the specific measurement of plasmin inhibitor activity. In summary, a plasma deficient in plasmin inhibitor should show an activity close to 0%. Plasma containing only the non-plasminogen binding form of plasmin inhibitor should show an activity nearby the activity of a plasma deficient for plasmin inhibitor. Other inhibitors of plasmin, like a 2 -macroglobulin, antithrombin in the presence of heparin, and C1-esterase inhibitor should not interfere in the assay at the level usually found in pathological conditions or at the higher normal level.
目前缺乏用于纤溶参数特定测量的成熟标准。纤溶小组委员会代表SSC启动了一个制定纤溶变量特定测量标准的过程。本报告描述了纤溶酶抑制剂活性特定测量的标准。总之,缺乏纤溶酶抑制剂的血浆应显示活性接近0%。仅含有纤溶酶抑制剂非纤溶酶原结合形式的血浆应显示出与缺乏纤溶酶抑制剂的血浆活性相近的活性。其他纤溶酶抑制剂,如α2-巨球蛋白、肝素存在时的抗凝血酶和C1酯酶抑制剂,在病理状况下通常发现的水平或较高正常水平下不应干扰该测定。